Last updated on September 2020

Study of Durvalumab + Tremelimumab Durvalumab and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Small Cell Lung Cancer
  • Age: Between 18 - 130 Years
  • Gender: Male or Female

Inclusion criteria:

  1. Histologically or cytologically documented limited-stage small cell lung cancer (stage I-III).
  2. Received 4 cycles of chemotherapy concurrent with radiotherapy, which must be completed within 1 to 42 days prior to randomization and the first dose of IP. Chemotherapy must contain platinum and IV etoposide. Radiotherapy must be either total 60-66 Gy over 6 weeks for the standard QD regimen or total 45 Gy over 3 weeks for hyperfractionated BD schedules.
  3. PCI may be delivered at the discretion of investigator and local standard of care, and must be conducted after the end of cCRT and completed between 1 to 42 days to first dose of IP.

4 .Have not progressed following definitive concurrent chemoradiation 5 .Life expectancy 12 weeks at Day 1. 6. ECOG 0 or 1 at enrolment.

Exclusion criteria:

  1. Extensive-stage SCLC
  2. Active or prior documented autoimmune or inflammatory disorders
  3. Uncontrolled intercurrent illness, including but not limited to interstitial lung disease.
  4. Active infection including tuberculosis, HIV, hepatitis B and C
  5. Patients who received sequential chemotherapy and radiotherapy (no overlap of RT with chemotherapy)

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.